489 related articles for article (PubMed ID: 22705769)
1. Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fraction.
Mori J; Basu R; McLean BA; Das SK; Zhang L; Patel VB; Wagg CS; Kassiri Z; Lopaschuk GD; Oudit GY
Circ Heart Fail; 2012 Jul; 5(4):493-503. PubMed ID: 22705769
[TBL] [Abstract][Full Text] [Related]
2. ANG II causes insulin resistance and induces cardiac metabolic switch and inefficiency: a critical role of PDK4.
Mori J; Alrob OA; Wagg CS; Harris RA; Lopaschuk GD; Oudit GY
Am J Physiol Heart Circ Physiol; 2013 Apr; 304(8):H1103-13. PubMed ID: 23396452
[TBL] [Abstract][Full Text] [Related]
3. Impact of the renin-angiotensin system on cardiac energy metabolism in heart failure.
Mori J; Zhang L; Oudit GY; Lopaschuk GD
J Mol Cell Cardiol; 2013 Oct; 63():98-106. PubMed ID: 23886814
[TBL] [Abstract][Full Text] [Related]
4. Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy.
Zhang L; Jaswal JS; Ussher JR; Sankaralingam S; Wagg C; Zaugg M; Lopaschuk GD
Circ Heart Fail; 2013 Sep; 6(5):1039-48. PubMed ID: 23861485
[TBL] [Abstract][Full Text] [Related]
5. SIRT2 Acts as a Cardioprotective Deacetylase in Pathological Cardiac Hypertrophy.
Tang X; Chen XF; Wang NY; Wang XM; Liang ST; Zheng W; Lu YB; Zhao X; Hao DL; Zhang ZQ; Zou MH; Liu DP; Chen HZ
Circulation; 2017 Nov; 136(21):2051-2067. PubMed ID: 28947430
[TBL] [Abstract][Full Text] [Related]
6. Specific role of the extracellular signal-regulated kinase pathway in angiotensin II-induced cardiac hypertrophy in vitro.
Aoki H; Richmond M; Izumo S; Sadoshima J
Biochem J; 2000 Apr; 347 Pt 1(Pt 1):275-84. PubMed ID: 10727428
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction.
Ainscough JF; Drinkhill MJ; Sedo A; Turner NA; Brooke DA; Balmforth AJ; Ball SG
Cardiovasc Res; 2009 Feb; 81(3):592-600. PubMed ID: 18703536
[TBL] [Abstract][Full Text] [Related]
8. The C-terminus of the long AKAP13 isoform (AKAP-Lbc) is critical for development of compensatory cardiac hypertrophy.
Taglieri DM; Johnson KR; Burmeister BT; Monasky MM; Spindler MJ; DeSantiago J; Banach K; Conklin BR; Carnegie GK
J Mol Cell Cardiol; 2014 Jan; 66():27-40. PubMed ID: 24161911
[TBL] [Abstract][Full Text] [Related]
9. The metabolic modulators, Etomoxir and NVP-LAB121, fail to reverse pressure overload induced heart failure in vivo.
Schwarzer M; Faerber G; Rueckauer T; Blum D; Pytel G; Mohr FW; Doenst T
Basic Res Cardiol; 2009 Sep; 104(5):547-57. PubMed ID: 19294446
[TBL] [Abstract][Full Text] [Related]
10. Uncoupling of glycolysis from glucose oxidation accompanies the development of heart failure with preserved ejection fraction.
Fillmore N; Levasseur JL; Fukushima A; Wagg CS; Wang W; Dyck JRB; Lopaschuk GD
Mol Med; 2018 Mar; 24(1):3. PubMed ID: 30134787
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling.
Izumiya Y; Kim S; Izumi Y; Yoshida K; Yoshiyama M; Matsuzawa A; Ichijo H; Iwao H
Circ Res; 2003 Oct; 93(9):874-83. PubMed ID: 14551246
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensin-converting enzyme 2-null mice.
Patel VB; Bodiga S; Fan D; Das SK; Wang Z; Wang W; Basu R; Zhong J; Kassiri Z; Oudit GY
Hypertension; 2012 Jun; 59(6):1195-203. PubMed ID: 22508831
[TBL] [Abstract][Full Text] [Related]
13. G1 cyclins are involved in the mechanism of cardiac myocyte hypertrophy induced by angiotensin II.
Nozato T; Ito H; Tamamori M; Adachi S; Abe S; Marumo F; Hiroe M
Jpn Circ J; 2000 Aug; 64(8):595-601. PubMed ID: 10952156
[TBL] [Abstract][Full Text] [Related]
14. The renin-angiotensin system and experimental heart failure.
Wollert KC; Drexler H
Cardiovasc Res; 1999 Sep; 43(4):838-49. PubMed ID: 10615411
[TBL] [Abstract][Full Text] [Related]
15. Preservation of myocardial fatty acid oxidation prevents diastolic dysfunction in mice subjected to angiotensin II infusion.
Choi YS; de Mattos AB; Shao D; Li T; Nabben M; Kim M; Wang W; Tian R; Kolwicz SC
J Mol Cell Cardiol; 2016 Nov; 100():64-71. PubMed ID: 27693463
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction.
Zhong J; Basu R; Guo D; Chow FL; Byrns S; Schuster M; Loibner H; Wang XH; Penninger JM; Kassiri Z; Oudit GY
Circulation; 2010 Aug; 122(7):717-28, 18 p following 728. PubMed ID: 20679547
[TBL] [Abstract][Full Text] [Related]
17. Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling.
Di Zhang A; Nguyen Dinh Cat A; Soukaseum C; Escoubet B; Cherfa A; Messaoudi S; Delcayre C; Samuel JL; Jaisser F
Hypertension; 2008 Dec; 52(6):1060-7. PubMed ID: 18981328
[TBL] [Abstract][Full Text] [Related]
18. Differential role of TIMP2 and TIMP3 in cardiac hypertrophy, fibrosis, and diastolic dysfunction.
Fan D; Takawale A; Basu R; Patel V; Lee J; Kandalam V; Wang X; Oudit GY; Kassiri Z
Cardiovasc Res; 2014 Jul; 103(2):268-80. PubMed ID: 24692173
[TBL] [Abstract][Full Text] [Related]
19. Evidence for the importance of adiponectin in the cardioprotective effects of pioglitazone.
Li P; Shibata R; Unno K; Shimano M; Furukawa M; Ohashi T; Cheng X; Nagata K; Ouchi N; Murohara T
Hypertension; 2010 Jan; 55(1):69-75. PubMed ID: 19933924
[TBL] [Abstract][Full Text] [Related]
20. Dyrk1a regulates the cardiomyocyte cell cycle via D-cyclin-dependent Rb/E2f-signalling.
Hille S; Dierck F; Kühl C; Sosna J; Adam-Klages S; Adam D; Lüllmann-Rauch R; Frey N; Kuhn C
Cardiovasc Res; 2016 Jun; 110(3):381-94. PubMed ID: 27056896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
